DCP
Davern Capital Partners Portfolio holdings
AUM
$309M
This Fund
S&P 500
1 Year Est. Return
–
AUM
$309M
AUM Growth
–
Holding
14
Top Buys
| 1 | +$51.5M | |
| 2 | +$37.4M | |
| 3 | +$35.6M | |
| 4 |
Royalty Pharma
RPRX
|
+$32.1M |
| 5 |
argenx
ARGX
|
+$30.5M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pfizer
PFE
$154B
| $50.9M | 16.44% |
+2,042,242
|
|
||
2
Regeneron Pharmaceuticals
REGN
$80.4B
| $40.5M | 13.08% |
+52,420
|
|
||
3
BioNTech
BNTX
$27.2B
| $35.3M | 11.43% |
+371,216
|
|
||
|
4
Royalty Pharma
RPRX
$19.4B
| $32.5M | 10.5% |
+840,650
|
|
||
|
5
argenx
ARGX
$47.3B
| $30M | 9.7% |
+35,685
|
|
||
6
Legend Biotech
LEGN
$3.54B
| $23M | 7.43% |
+1,056,668
|
|
||
7
Roivant Sciences
ROIV
$20.1B
| $22.3M | 7.21% |
+1,028,298
|
|
||
8
Ionis Pharmaceuticals
IONS
$12.9B
| $18.9M | 6.1% |
+238,477
|
|
||
9
Natera
NTRA
$29.6B
| $18M | 5.83% |
+78,650
|
|
||
10
Eli Lilly
LLY
$952B
| $8.93M | 2.89% |
+8,307
|
|
||
11
Viridian Therapeutics
VRDN
$2.73B
| $8.14M | 2.63% |
+261,615
|
|
||
12
Mineralys Therapeutics
MLYS
$2.26B
| $7.64M | 2.47% |
+210,648
|
|
||
13
CG Oncology
CGON
$4.62B
| $6.73M | 2.17% |
+162,005
|
|
||
|
ABVX
14
Abivax
ABVX
$9.44B
| $6.54M | 2.11% |
+48,502
|
|